Teladoc Health, Inc. · NYSE:TDOC
Teladoc Health — Q1 2026 Earnings Presentation
14 slides from Teladoc Health's earnings presentation, Apr 29, 2026
Slide 1: 1Q-26 Quarterly Results
1Q-26 Quarterly Results
Slide 2: Cautionary Note
Cautionary Note • This presentation contains, and the officers of Teladoc Health, Inc. (the “Company” or “Teladoc Health”) may make, “forward-looking” statements that are based on management’s beliefs and assumptions and on information currently available to management. These forward-looking stateme
Slide 3: Key Financial Data
Key Financial Data 1Q-26 Adj. 1Q-26 Revenue of 1Q-26 Net loss per EBITDA(2) of $614M, (2)% y/y share of $(0.36)(1) $58.2M, 0% y/y FY-26 Revenue outlook range FY-26 Net loss per share FY-26 Adj. EBITDA outlook of $2,481M to $2,576M outlook range of range of $267M to $306M $(1.05) to $(0.75) • 2Q-26 R
Slide 4: 1Q-26 Consolidated Revenue & Adj. EBITDA
1Q-26 Consolidated Revenue & Adj. EBITDA Revenue ($ millions) Adj. EBITDA ($ millions)(1) $70 $700 $629 $614 $60 $58.1 $58.2 $600 $500 $50 $400 $40 $300 $30 $200 $20 $100 $10 $0 $0 1Q-25 1Q-26 1Q-25 1Q-26 (1) See reconciliation of GAAP to non-GAAP measures included in the Appendix of this presentati
Slide 5: Quarterly Segment Results
Quarterly Segment(1) Results Integrated Care Segment Revenue ($ millions) BetterHelp Segment Revenue ($ millions) $600 $300 $240 $240 $237 $233 $409 $218 $389 $392 $390 $395 $400 $200 $200 $100 $0 $0 1Q-25 2Q-25 3Q-25 4Q-25 1Q-26 1Q-25 2Q-25 3Q-25 4Q-25 1Q-26 Integrated Care Segment Adjusted EBITDA
Slide 6: 1Q-26 Revenue: U.S. & International
1Q-26 Revenue: U.S. & International U.S. Revenue ($ millions) International Revenue ($ millions) $600 $150 $525 $492 $122 $500 $125 $104 $400 $100 $300 $75 $200 $50 $100 $25 $0 $0 1Q-25 1Q-26 1Q-25 1Q-26 © Teladoc Health, Inc. All rights reserved. 6
Slide 7: Quarterly Key Operating Metrics
Quarterly Key Operating Metrics U.S. Integrated Care Members(1) (millions) BetterHelp Paying Users(2) (thousands) 150m 600k 102.5 102.4 102.5 101.8 101.2 397 388 382 375 361 100m 400k 50m 200k 0m 0k 1Q-25 2Q-25 3Q-25 4Q-25 1Q-26 1Q-25 2Q-25 3Q-25 4Q-25 1Q-26 Average Monthly Revenue per Chronic Care
Slide 8: Quarterly Adjusted EBITDA & Adjusted EBITDA Margin
Quarterly Adjusted EBITDA & Adjusted EBITDA Margin Adj. EBITDA(1) ($ millions) & Adj. EBITDA Margin $100 16% 13.0% 14% $75 11.0% 11.2% 12% 9.2% 9.5% 10% $50 8% $83.8 6% $69.3 $69.9 $58.1 $58.2 $25 4% 2% $0 0% 1Q-25 2Q-25 3Q-25 4Q-25 1Q-26 Adj. EBITDA Adj. EBITDA Margin (1) See reconciliation of GAAP
Slide 9: Balance Sheet and Cash Flow Highlights
Balance Sheet and Cash Flow Highlights • Cash and Cash Equivalents (as of March 31, 2026): $751M • Convertible Senior Notes (as of March 31, 2026): $996M • Operating Cash Flow (1Q-26): $10M • Free Cash Flow (1) (1Q-26): $(26)M (1) See reconciliation of GAAP to non-GAAP measures included in the Appen
Slide 10: Outlook: 2Q-26 and FY-26
Outlook: 2Q-26 and FY-26 2Q-26 Y/Y % Growth FY-26 Y/Y % Growth Revenue ($M) $597 to $626 (6)% to (1)% $2,481 to $2,576 (2)% to 2% Net loss per share $(0.30) to $(0.20) NM $(1.05) to $(0.75) NM Adj. EBITDA ($M) $55 to $67 (20)% to (3)% $267 to $306 (5)% to 9% US Integrated Care 98.5 to 100 (4)% to (2
Slide 11: Appendix
Appendix Teladoc HEALTH
Slide 12: Reconciliation of GAAP Net Loss to Adjusted EBITDA
Reconciliation of GAAP Net Loss to Adjusted EBITDA 1Q-25 2Q-25 3Q-25 4Q-25 1Q-26 Net loss $(93,012) $(32,660) $(49,507) $(25,143) $(63,837) Add: Provision for income taxes (18,255) (7,763) (715) (8,475) 2,995 Other expense (income), net (2,435) (8,371) 815 (378) 196 Interest expense 5,765 4,473 4,52
Slide 13: Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow
Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow 1Q-26 Net cash provided by operating activities $9,516 Capital expenditures (1,660) Capitalized software development costs (34,162) Capex (35,822) Free Cash Flow $(26,306) (in 000s) © Teladoc Health, Inc. All rights r
Slide 14: Teladoc Health
Teladoc HEALTH